3 hours Ago By ABMN Staff
Shares of Hologic, Inc. ( NASDAQ:HOLX – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat.com reports.
Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $89.91.
A number of brokerages have recently weighed in on HOLX. Leerink Partners dropped their price target on Hologic from $95.00 to $90.
00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Raymond James upped their price target on shares of Hologic from $93.00 to $95.
00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Royal Bank of Canada lifted their price objective on shares of Hologic from $86.00 to $89.
00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th.
Finally, JPMorgan Chase & Co. lifted their price target on Hologic from $92.00 to $94.
00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Read Our Latest Stock Analysis on HOLX Institutional Inflows and Outflows Hologic Trading Down 0.9 % NASDAQ:HOLX opened at $79.
00 on Wednesday. The stock has a market capitalization of $18.35 billion, a price-to-earnings ratio of 23.
72, a PEG ratio of 2.49 and a beta of 0.98.
Hologic has a 52 week low of $67.59 and a 52 week high of $84.67.
The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.
49. The firm has a 50 day moving average of $80.38 and a 200 day moving average of $78.
38. Hologic ( NASDAQ:HOLX – Get Free Report ) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.
01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.
79% and a net margin of 19.59%. The firm had revenue of $987.
90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business posted $0.
89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year.
As a group, sell-side analysts anticipate that Hologic will post 4.27 earnings per share for the current fiscal year. Hologic Company Profile ( Get Free Report Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. Recommended Stories Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.
com's FREE daily email newsletter ..
